Response to Comments: MolDX: Oncotype DX AR-V7 Nucleus Detect for Men with Metastatic Castrate Resistant Prostate Cancer (MCRPC)

This document is an administrative notice responding to comments and providing the timeline for the MolDX LCD (DL37701) for Oncotype DX AR-V7 Nucleus Detect in men with metastatic castrate-resistant prostate cancer; it does not contain clinical coverage criteria. To determine coverage indications, limitations, documentation requirements, and frequency limits, the referenced LCD DL37701 (finalized 03/25/2019) must be reviewed; manual extraction from that LCD is required.